Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI Map
The target’s significance, according to Recursion and its partners, rests in its potential to expand the universe of neuroscience treatments beyond the handful of familiar targets in the space. While more than three billion people are affected by neurological conditions worldwide, only one in 40 neuroscience drugs to ever reach the clinic have been approved. The post Recursion Partners with…
Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI Map. The 4.5 year, up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked a milestone Wednesday when plans were announced for Recursion and Genentech to co-develop a neuroscience small molecule early discovery program based on the first validated target discovered through an AI map they created to find new targets in a long-challenging therapeutic area.
Genentech has exercised the collaboration’s first validated target option after accepting from Recursion a validation package for the target. That acceptance will trigger a $3 million milestone payment from the biopharma giants to Recursion. That latest payment raises to $216 million the total cash paid out by the biopharma giants to Recursion since the AI-based drug developer joined with the pharma giant and its subsidiary to launch their partnership in 2021.
Brief written by urgent.news from GEN Biotechnology's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
